journal of men's health
Volume 5, Issue 1 , Pages 18-22 , March 2008

Metabolic risk factors as a connecting link for men's health issues

References 

  1. Oganov RG. [The concept of the risk factors as the basis for the prevention of cardiovascular diseases]. Vrach [Physician]. 2001;7:3–6[In Russian]
  2. Oganov RG, Maslennikova GYa. [The development of preventive cardiology in Russia]. Kardiovaskulyarnaya terapiya i profilaktika. [Cardiovasc Ther Prevent]. 2004;3:11–14[In Russian]
  3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10(Supp 1):S1–S10
  4. Shalnova S. [The issues of the treatment of hypertension]. Kardiovaskulyarnaya terapiya i profilaktika. [Cardiovasc Ther Prevent]. 2003;2(3):17–21[In Russian]
  5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case-control study. Lancet. 2004;364:937–952
  6. Oganov RG, Mamedov MN. [The school-seminar in diagnosis and therapy of metabolic syndrome]. Posobie dlya vrachei. Meditsinskaya Kniga, Moskva [Physician's Manual: Medical Book, Moscow] 2007: 18–20 [In Russian].
  7. Kylin E. Studien uber das Hypertonie, Hyperglykamie, Hyperurikamiesyndrom. Zentralbl Innere Med. 1923;7:105–112[In German]
  8. Lang G. [About Hypertension]. Arhiv gos. kliniki instituta dlya usovershenstvovaniya vrachei. L. [Arch State Institution for Refreshment of Physicians and Surgeons, Leningrad]. 1922;1:6–66[In Russian]
  9. Smith TR, Elmendorf JS, David TS, Turinsky J. Growth hormone-induced insulin resistance: role of the insulin receptor, IRS1, GLUT1, GLUT4. Am J Physiol. 1997;272:E1071–E1079
  10. Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  11. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med. 2006;38(1):34–41
  12. Zimmet P, Shaw J, Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic Med. 2003;20(9):693–702
  13. Mamedov M, Shalnova S, Oganov R. Metabolic syndrome prevalence in Russia: preliminary results of a cross-sectional population study. Diabetes Vasc Dis Res. 2007;4(Suppl. 1):S46–S47
  14. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709–2716
  15. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2005;28(2):385–390
  16. Phillips GB. Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci USA. 1977;74:1729–1733
  17. Pagotto U, Gamnineri A, Pelusi C, Genghini S, Cacciari M, Otto B, et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003;88(9):4139–4143
  18. Laaksonen DE, Niskanen R, Purnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex-hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036–1041
  19. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care. 2002;25:55–60
  20. Mazo E, Gamidov S, Mamedov M, Iremashvili V. Association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and erectile dysfunction in patients with metabolic syndrome. Int J Impot Res. 2008;20(1):68–72
  21. Haffner SM, Valdez RA, Mykkänen L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism. 1994;43:599–603
  22. Shabsigh R, Arver S, Channer KS, Eardley I, Fabbri A, Gooren L, et al. Sexual health as a portal to men's health: a problem turned around into an opportunity. Int J Clin Pract. 2008;62(2):179–181
  23. Kapoor D, Codween E, Channer K. Testosterone replacement improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906
  24. Zitzmann M, Nieschlag E. Effects of androgen replacement on metabolism and physical performances in male hypogonadism. J Endocrinol Invest. 2003;26(9):886–892Review
  25. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–876
  26. Lunenfeld B. Testosterone deficiency and the metabolic syndrome. Aging Male. 2007;10(2):53–56

PII: S1875-6867(08)00008-0

doi: 10.1016/j.jomh.2008.01.003

journal of men's health
Volume 5, Issue 1 , Pages 18-22 , March 2008

Article Tools